Table 3.

Univariate analyses

Characteristic	Overall Survival			Disease-free Survival
	HR	95% CI	P	HR	95% CI	P
Age (years)	1.030	1.008 – 1.051	0.006	1.030	1.009 – 1.052	0.005
BMI (kg/m2)	1.009	0.985 – 1.033	0.482	0.991	0.966 – 1.017	0.507
Race
Caucasian	1.0	-	-	1.0	-	-
African American	1.454	0.633 – 3.340	0.378	0.980	0.358 – 2.684	0.969
MSI
Negative	1.0	-	-	1.0	-	-
Positive	0.783	0.460 – 1.334	0.368	0.874	0.498 – 1.532	0.638
ATR mutation
Absent	1.0	-	-	1.0	-	-
Present	1.159	0.579 – 2.318	0.677	0.605	0.245 – 1.498	0.278
Tumor grade
1	1.0	-	-	1.0	-	-
2	1.281	0.733 – 2.240	0.385	1.302	0.753 – 2.250	0.345
3	2.767	1.582 – 4.841	<0.001	2.243	1.262 – 3.987	0.006
Tumor grade
1	1.0	-	-	1.0	-	-
2 or 3	1.750	1.059 – 2.892	0.029	1.597	0.970 – 2.627	0.066
Stage
IA	1.0	-	-	1.0	-	-
IB/IC	1.759	0.695 – 4.451	0.233	1.679	0.662 – 4.261	0.275
II	1.825	0.597 – 5.579	0.291	1.610	0.511 – 5.074	0.416
III/IV	3.476	1.349 – 8.960	0.010	3.360	1.301 – 8.680	0.012
Stage
Early (stage I or II)	1.0	-	-	1.0	-	-
Late (stage III or IV)	2.105	1.347 – 3.289	0.001	2.146	1.360 – 3.385	0.001
LVSI
No	1.0	-	-	1.0	-	-
Yes	2.464	1.593 – 3.810	<0.001	2.020	1.302 – 3.135	0.002
Myometrial invasion
None	1.0	-	-	1.0	-	-
Inner half	1.148	0.479 – 2.751	0.758	1.062	0.470 – 2.402	0.884
Outer half	3.172	1.334 – 7.544	0.009	2.286	1.004 – 5.205	0.049
Serosa	8.654	3.079 – 24.326	<0.001	5.804	2.035 – 16.555	0.001
Adjuvant treatment
No	1.0	-	-	1.0	-	-
Yes	1.368	0.889 – 2.106	0.154	1.476	0.947 – 2.299	0.085